These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33662260)

  • 1. Highlights of HIVR4P // Virtual.
    Harris P; Henderson R
    Lancet HIV; 2021 Mar; 8(3):129. PubMed ID: 33662260
    [No Abstract]   [Full Text] [Related]  

  • 2. Ending sexual HIV transmission: lessons learned from perinatal HIV.
    Weber S; Grant RM
    J Assoc Nurses AIDS Care; 2015; 26(5):520-5. PubMed ID: 26096627
    [No Abstract]   [Full Text] [Related]  

  • 3. Changing from Tenofovir/Emtricitabine to Cabotegravir for Pre Exposure Prophylaxis for HIV in Men who have Sex with Men: A Cost Utility Analysis from an Endemic Country.
    Joob B; Wiwanikit V
    J Assoc Physicians India; 2022 Feb; 70(2):11-12. PubMed ID: 35436834
    [No Abstract]   [Full Text] [Related]  

  • 4. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
    Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
    Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance.
    Hsiao YY; Huang YC; Chang SY; Kuo CH; Chang SF; Lin YT; Luo YZ; Lee YL; Hung CC
    J Microbiol Immunol Infect; 2021 Aug; 54(4):755-757. PubMed ID: 33597075
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach.
    Seidman DL; Weber S; Cohan D
    J Int AIDS Soc; 2017 Mar; 20(Suppl 1):21295. PubMed ID: 28361503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is injectable PrEP superior to oral therapy for HIV protection?
    Kriegel D; Daniels A; Seehusen DA
    J Fam Pract; 2023 Jul; 72(6):264-265. PubMed ID: 37549401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PURLs: On-demand pill protocol protects against HIV.
    Justesen K; Prasad S
    J Fam Pract; 2016 Aug; 65(8):556-8. PubMed ID: 27660840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NHS England should reconsider PrEP decision.
    The Lancet Hiv
    Lancet HIV; 2016 May; 3(5):e191. PubMed ID: 27126479
    [No Abstract]   [Full Text] [Related]  

  • 11. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
    Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM
    J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New PrEP formulation approved…but only for some.
    The Lancet Hiv
    Lancet HIV; 2019 Nov; 6(11):e723. PubMed ID: 31672278
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
    Mizushima D; Gatanaga H; Oka S
    Hepatology; 2023 Nov; 78(5):E98. PubMed ID: 37560991
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter to the Editor: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
    Hung CT; Hsu SJ; Liu CJ
    Hepatology; 2023 Nov; 78(5):E97. PubMed ID: 37738208
    [No Abstract]   [Full Text] [Related]  

  • 17. Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.
    Quah SP; McIntyre M; Wood A; Mc Mullan K; Rafferty P
    HIV Med; 2021 Feb; 22(2):e5-e6. PubMed ID: 33063431
    [No Abstract]   [Full Text] [Related]  

  • 18. Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin.
    Ahouada C; Diabaté S; Mondor M; Hessou S; Guédou FA; Béhanzin L; Batona G; Gning NN; Zannou DM; Alary M
    BMC Public Health; 2020 Aug; 20(1):1267. PubMed ID: 32819335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When is good good enough for HIV-1 prophylaxis?
    Buchbinder S
    Lancet Infect Dis; 2014 Nov; 14(11):1024-1025. PubMed ID: 25300861
    [No Abstract]   [Full Text] [Related]  

  • 20. Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate.
    Ruone S; Paxton L; McLaurin T; Taylor A; Hanson D; Heneine W; Brooks JT; García-Lerma JG
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):129-32. PubMed ID: 26689970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.